SEARCH

Current Edition

experimental drug

Mirati gives first look at KRAS drug combination in lung cancer

Mirati’s drug, called adagrasib, is particularly closely watched. After Lumakras, which won U.S. approval earlier this year, it’s the most advanced experimental drug targeting a …

Continue Reading →